EA201891204A1 - ANTIBODY AGAINST ALPHA-V INTEGRINE FOR THE TREATMENT OF FIBROSIS AND / OR FIBROUS DISORDERS - Google Patents

ANTIBODY AGAINST ALPHA-V INTEGRINE FOR THE TREATMENT OF FIBROSIS AND / OR FIBROUS DISORDERS

Info

Publication number
EA201891204A1
EA201891204A1 EA201891204A EA201891204A EA201891204A1 EA 201891204 A1 EA201891204 A1 EA 201891204A1 EA 201891204 A EA201891204 A EA 201891204A EA 201891204 A EA201891204 A EA 201891204A EA 201891204 A1 EA201891204 A1 EA 201891204A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fibrosis
treatment
relates
integrine
systemic sclerosis
Prior art date
Application number
EA201891204A
Other languages
Russian (ru)
Inventor
Ильхан Челик
Айке Штауб
Мириам Урбан
Забине Рааб
Айлин Сами
Эндрю Бендер
Джорджианна Хиггинботэм
Инь У
Дайгэнь Сюй
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201891204A1 publication Critical patent/EA201891204A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q3/00—Condition responsive control processes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Изобретение относится к профилактике и/или лечению фиброза и/или фиброзных заболеваний посредством антител. Главным образом, изобретение относится к введению антитела против интегрина альфа-v (рецептора) пациентам, страдающим от фиброза и/или фиброзных заболеваний, включая, но не ограничиваясь этим, системный склероз (СС). В частности, настоящее изобретение относится к лечению фиброзных заболеваний кожи, лёгких, сердца, печени и/или почек посредством указанного антитела. Более того, в частности, настоящее изобретение относится к введению рекомбинантного, деиммунизированного моноклонального антитела, направленно воздействующего на αv-интегрины, пациентам, страдающим от системного склероза, включая, но не ограничиваясь этим, системный склероз кожи, лёгких, сердца и/или почек, посредством введения антитела DI17E6 против интегрина альфа-v и его структурных мутантов или модификаций.The invention relates to the prevention and / or treatment of fibrosis and / or fibrotic diseases by means of antibodies. Mainly, the invention relates to the administration of an anti-integrin alpha-v (receptor) antibody to patients suffering from fibrosis and / or fibrosis diseases, including but not limited to systemic sclerosis (CC). In particular, the present invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver, and / or kidneys with said antibody. Moreover, in particular, the present invention relates to the introduction of a recombinant, de-immunized monoclonal antibody directed against αv-integrins in patients suffering from systemic sclerosis, including, but not limited to, systemic sclerosis of the skin, lungs, heart and / or kidneys, through the introduction of antibodies DI17E6 against integrin alpha-v and its structural mutants or modifications.

EA201891204A 2016-04-12 2016-11-22 ANTIBODY AGAINST ALPHA-V INTEGRINE FOR THE TREATMENT OF FIBROSIS AND / OR FIBROUS DISORDERS EA201891204A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16164879 2016-04-12
PCT/EP2016/001970 WO2017088974A2 (en) 2015-11-23 2016-11-22 Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders

Publications (1)

Publication Number Publication Date
EA201891204A1 true EA201891204A1 (en) 2019-03-29

Family

ID=55755374

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891204A EA201891204A1 (en) 2016-04-12 2016-11-22 ANTIBODY AGAINST ALPHA-V INTEGRINE FOR THE TREATMENT OF FIBROSIS AND / OR FIBROUS DISORDERS

Country Status (11)

Country Link
EP (1) EP3380520A2 (en)
KR (1) KR20180081617A (en)
CN (1) CN108473582A (en)
AU (1) AU2016360661B2 (en)
BR (1) BR112018010337A2 (en)
CA (1) CA3005764A1 (en)
EA (1) EA201891204A1 (en)
MX (1) MX2018006269A (en)
SG (1) SG11201804243QA (en)
TW (1) TW201720843A (en)
WO (1) WO2017088974A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210347898A1 (en) * 2018-10-09 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
JP7317379B2 (en) * 2019-01-04 2023-07-31 国立大学法人京都大学 Examination method for ulcerative colitis and primary sclerosing cholangitis
US20220370545A1 (en) * 2019-09-20 2022-11-24 North Carolina State University Integrin receptor alpha v beta 3 and its ligand involved in chronic itch
EP4323401A1 (en) * 2021-04-12 2024-02-21 Syddansk Universitet Mfap4 and treatment of fibrosis
CN116955967B (en) * 2023-09-20 2023-12-08 成都无糖信息技术有限公司 System and method for simulating investigation and adjustment in network target range

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072614B (en) * 2005-07-08 2017-04-26 生物基因Ma公司 Anti-alpha[v]beta[6] antibodies and uses thereof
PL2167128T3 (en) * 2007-07-17 2013-03-29 Merck Patent Gmbh Engineered anti-alpha v- integrin hybrid antibodies
WO2010008543A2 (en) * 2008-07-15 2010-01-21 Trustees Of Dartmouth College Molecular signatures for diagnosing scleroderma
SI2672994T1 (en) * 2011-02-11 2018-09-28 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
PT2714735T (en) * 2011-06-03 2021-10-26 Xoma Technology Ltd Antibodies specific for tgf-beta
AR090339A1 (en) * 2012-03-27 2014-11-05 Genentech Inc METHODS OF FORECAST, DIAGNOSIS AND TREATMENT OF IDIOPATIC PULMONARY FIBROSIS

Also Published As

Publication number Publication date
CN108473582A (en) 2018-08-31
WO2017088974A3 (en) 2017-07-13
EP3380520A2 (en) 2018-10-03
AU2016360661A1 (en) 2018-07-05
MX2018006269A (en) 2018-09-05
CA3005764A1 (en) 2017-06-01
BR112018010337A2 (en) 2018-12-04
SG11201804243QA (en) 2018-06-28
KR20180081617A (en) 2018-07-16
TW201720843A (en) 2017-06-16
AU2016360661B2 (en) 2023-12-14
WO2017088974A2 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
EA201891204A1 (en) ANTIBODY AGAINST ALPHA-V INTEGRINE FOR THE TREATMENT OF FIBROSIS AND / OR FIBROUS DISORDERS
MX2020003888A (en) Fully-human post-translationally modified antibody therapeutics.
CO2019007844A2 (en) Novel human transferrin receptor antibody capable of penetrating the blood brain barrier
EA201890162A1 (en) ANTIBODIES TO CD40 WITH ENHANCED AGONISTIC ACTIVITY
AR103782A1 (en) INTEGRINE b7 ANTAGONISTS AND METHODS OF TREATMENT OF CROHN'S DISEASE
UA115540C2 (en) Anti il-36r antibodies
UA118453C2 (en) Modulation of tumor immunity
NZ728265A (en) Methods to enhance organ transplant and antibody therapies
MX2019004779A (en) Pharmaceutical composition for cancer treatment and/or prevention.
NZ630363A (en) Anti-kit antibodies and uses thereof
EA202190378A1 (en) ANTIBODIES AGAINST IFNAR1 FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MX2023005465A (en) Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors.
EA201300131A1 (en) COMBINED PHARMACEUTICAL COMPOSITION AND METHODS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASES OR CONDITIONS
UA117097C2 (en) Antibodies to bradykinin b1 receptor ligands
EA201791227A1 (en) DOSING MODE OF MAdCAM ANTAGONISTS
WO2019112347A3 (en) Antibody or antigen binding fragment thereof for specifically recognizing b cell malignancy, chimeric antigen receptor comprising same, and use thereof
WO2018111670A3 (en) Antibodies to human alpha-synuclein
PH12018500131A1 (en) Il22 immunoconjugates
MX2021012160A (en) Anti-integrin antibodies and uses thereof.
CL2022000786A1 (en) Treatment methods to modify hemodynamics
RU2015134422A (en) APPLICATION OF LEVOCYTHIRIZINE AND MONTELUKAST IN THE TREATMENT OF VASCULITIS
BR112016023980A2 (en) vnar recombinant monoclonal antibodies that neutralize vascular endothelial growth factor (vegf)
EA201992348A1 (en) ANTIGEN-BINDING PROTEINS INTERACTING WITH JAGGED1
MX2020002750A (en) Il-6r antibody and antigen binding fragment thereof and medical use.
MX2021004120A (en) Dosage regimen for tfpi antagonists.